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The Effect of Ketoconazole on Amphotericin B in a Model of
Disseminated Aspergillosis
Andreas Schaffner and Paul G. Frick From the Department of Medicine, University of Zurich,
Zurich, Switzerland
The potential of ketoconazole prophylaxis to antagonize the activity of amphotericin B
against aspergilli was investigated in vitro and in neutropenic mice. Exposure of Asper-
gillus fumigatus (six strains) and of Aspergillus f/avus or Aspergillus niger to ketocona-
zole resulted in a uniform increase of the minimal fungicidal activity of amphotericin
B, from 0.15-0.63 mg/liter to >2.5 mg/liter in a microwell assay. To test the relevance
of this antagonism in vivo,wechallenged neutropenic mice iv with a lethal dose of conidia
from two strains of A. fumigatus and then treated the mice first with ketoconazole and
then with amphotericin B or amphotericin B plus ketoconazole. Pretreatment with
ketoconazole for 48 hr completely abolished the protective effect of a subsequent therapy
with amphotericin B, whether ketoconazole therapy was stopped (P < .(01) or not
(P < .001). Ketoconazole given alone had no significant effect on survival. Our data show
that ketoconazole not only antagonized the fungicidal activity of amphotericin B in vitro
but also abolished in vivo the protective effect of the only drug shown to be useful in
the therapy of aspergillosis. The clinicalimportance of this antagonism, which is not limited
to Aspergilli in vitro, requires careful consideration before ketoconazole prophylaxis can
be recommended for patients at high risk of developing invasive opportunistic fungal
infections.
Patients with marked and prolonged neutropenia are
at high risk of developing an opportunistic myco-
sis. Thus prevention of fungal infection has become
a major concern in this population. At necropsy,
24070-64070 of patients with acute myelogenousleuke-
mia are found to have an invasive fungal infection
[1-8]. In some centers [1-3] opportunistic yeasts,
commonly species of Candida, prevail, whereas in
others [6-8] aspergilli are the leading opportunistic
fungal pathogens.
Efforts to prevent candidiasis or aspergillosis
might differ markedly because the former commonly
results from mucosal invasion after colonization [9]
and the latter usually is a consequence of inhalation
of spores [10].Thus, suppression of mucosal coloni-
zation cannot be expected to prevent aspergillosis.
Furthermore, aspergilli and species of Candida dif-
fer in their susceptibility to antimycotic agents; e.g.,
Aspergilliare less susceptibleto imidazoles [11]. Thus
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it is not surprising that in a study [12] comparing
prophylaxis of fungal infections with ketoconazole
or miconazole in patients undergoing intensive an-
titumor chemotherapy, aspergillosis was discovered
in 24% of patients at necropsy.
Because imidazoles have the potential to an-
tagonize the antifungal activity of amphotericin B
[13-15] (the most effective drug for therapy of most
invasive opportunistic mycoses, including aspergil-
losis [16, 17]), we became interested in the question
of whether ketoconazole prophylaxis that was re-
cently advocated in neutropenic patients [12, 18, 19]
would influence the efficacy of a subsequent ther-
apy of aspergillosis with amphotericin B. We there-
fore investigated the effects of ketoconazole on the
susceptibility of aspergilli to amphotericin B in vitro
and in vivo in neutropenic mice.
Materials and Methods
Organisms. Six clinical isolates of Aspergillus
fumigatus, all from immunocompromised patients
with invasive disease and all isolated at the Univer-
sity Hospital of Zurich, and a strain each of Asper-
gillus flavus and Aspergillus niger isolated from pa-
tients at the University Hospital in San Diego were
propagated, and suspensions of single spores were
prepared as previously described [10].
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Figure 1. Diagram of experimental antimycotic regi-
mens. Mice were immunosuppressed starting two days
before challenge with cortisone acetate (CA) and nitro-
gen mustard (HN 2 ) . Immediately after infection, mice
received ketoconazole or solvent by gavage for 24-48 hr
followed by either ketoconazole, amphotericin B plus
ketoconazole, amphotericin B, or solvents (carbox-
ymethylcellulose by gavage, 5070 glucose iv) for six days.
24-26 g. Cages were cleaned three times a week, and
acidified water and food pellets were offered ad
libitum.
Immunosuppression. To abolish the conidiaci-
dal activity of macrophages, mice were given a sin-
gle dose of 5 mg of cortisone acetate (gift from Merck
Sharp & Dohme, West Point, Pa) sc [10]. An-
timycelial defense was ablated by bone marrow sup-
pression with nitrogen mustard (Merck Sharp &
Dohme) [10]. In preliminary experiments we found
that iv injections (for three consecutive days) of 50 IJg
of nitrogen mustard before infection gavean optimal
neutropenic episode without spontaneous death and
gave neutrophil counts <10011J1 for the first four
days after the anticipated challenge (figure 1) with
a slow recovery of neutrophil counts over the next
five days.
Challenge. Mice were challenged iv withconidia
suspended in 0.5 ml of 0.15 M NaCl. Spores were
quantitated by hematocytometer counts and culture
of serial dilutions with the pour-plate technique [20].
In preliminary experiments we determined the LDso
and LD IO O of the two isolates of A. fumigatus that
were selected for the in vivo studies in the im-
munosuppressed mice, as previously described [10].
For isolate no. 1, the LD so was 8.4 X 102 and the
LD IO O was 4 x 104 spores; for isolate no. 4, the LDso
was 7.3 x 102 and the LD 100 was 3 X 104 spores.
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In vitro studies on the interaction of ketocona-
zole and amphotericin B. For in vitro use,
ketoconazole (gift from Janssen Pharmaceutica,
New Brunswick, NJ) and amphotericin B (pure crys-
talline form; gift from E. R. Squibb & Sons, Prince-
ton, NJ) were dissolved in dimethylsulfoxide
(DMSO) at a concentration of 1 mg/ml and were
diluted to the desired concentration in a mixture of
90070 Sabouraud dextrose broth (Difco, Detroit) and
10070 0.15 M phosphate buffer (SAB-PB; pH 7.4).
The fungicidal test was begun bydispensing 30-40
conidia, suspended in 100IJI of trypticase-soy broth
(Difco), into 300-IJI-flat -bottom clusterwell plates
(Nunk, Kamstrup, Denmark). Plates were incubated
at room temperature until the transformation of
spores into mycelia was completed (14-18 hr). Ger-
mination was verified for each wellby phase-contrast
microscopy. The plates were then centrifuged at
800 g for 15 min. The supernatant was aspirated
through a 23-gauge needle and replaced by ketocona-
zole in SAB-PB or in SAB-PB with the appropriate
concentration of DMSO. After incubation at 37 C
for the indicated time periods, plates were again cen-
trifuged and the supernatant replaced by serial di-
lutions of amphotericin B in SAB-PB or in SAB-PB
mixed with DMSO and were incubated for 24 hr at
37 C. Plates were then centrifuged again and the su-
pernatant was replaced by trypticase-soy broth to
promote fungal outgrowth. Plates were inspected
daily for six days for fungal colonies, and one drop
of 5070 aqueous methylene blue was added to each
well with fungal growth to prevent sporulation and,
thus, cross contamination. Results of minimal fun-
gicidal concentrations are given as the lowest con-
centration at which no fungal growth occurred within
six days after removal of amphotericin B. With the
exception of a rare skipwell, all wells were sterilized
at this concentration, whereas all wells produced
fungi at the next lower concentration. In initial ex-
periments wells were washed one to three times with
SAB-PB after the removal of ketoconazole or am-
photericin B, but washing had no influence on the
test results and was later omitted. Furthermore we
initially inspected the plates for up to three weeks,
but prolonged incubation did not produce more fun-
gal colonies.
Animals. Throughout the study female NMRI
mice (IVANOVAS, Kisslegg, Federal Republic of
Germany) were used. Mice were housed for at least
10days in our facility, and immunosuppression was
not started before the mice had reached a weight of
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For in vivo studies of the protective effects of the
antimycotic regimens, mice werechallenged with an
LD lOo •
Experimental antimycotic regimens. A dose of
2 mg of amphotericin B/kg per day was chosen on
the basis of a comparison of the antifungal activity
of plasma from groups of mice receiving graded
doses of the drug for three days and the antifungal
activity of plasma from two patients. To match the
antifungal activity of plasma from two patients
receiving 0.6 and 0.75 mg of amphotericin B/kg per
day against A. fumigatus 1 in our microwell assay,
we had to give mice 2 mg of amphotericin B/kg per
day; undiluted plasma was fungicidal and, at a 1:2
or 1:4 dilution, fungistatic. After 1 mg/kg per day,
undiluted plasma was only fungistatic and 0.5 mg/kg
was inactive when compared with normal human or
mouse plasma. A dose-range for ketoconazole was
chosen on the basis of a comparison of the fun-
gistatic activity of plasma obtained 2.5 hr after the
third daily dose of ketoconazole and the activity of
mouse plasma to which known concentrations of the
drug were added; the test organism we used was
Trichophyton mentagrophytes (gift from Dr. A. Po-
lak, Hoffmann La Roche, Basel, Switzerland). The
test was modified by reducing the incubation tem-
perature to 30 C, and the fungistatic activity was read
at 48 hr. Plasma from mice receiving 150 or 200 mg
of ketoconazole per day was as active as plasma
spiked with 3.5 mg of ketoconazole/liter but was less
active than plasma with 7 mg/liter. A daily dose of
100 mg of ketoconazole/kg resulted in fungistatic
activity identical to that of plasma to which 1.8 mg
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of ketoconazole/liter was added but less active than
plasma with 3.5 mg/liter added. Thus a daily
ketoconazole dose of 100-200 mg in mice resulted
in blood activities comparable to those of drug con-
centrations obtained in clinical therapy [21, 22].
The study design for the in vivo chemotherapeu-
tic trials are shown in figure 1.Ketoconazole (100-200
mg/kg per day) suspended in 0.2 ml of carbox-
ymethylcellulose with 0.01% Tween 80 was given by
gavage. Amphotericin B-deoxycholate (Squibb), in
a dose of 2 mg of amphotericin B/kg per day, was
injected iv in a volume of 0.5 ml of 5OJo glucose. For
better tolerance the dose was divided into two injec-
tions that were given at intervals of 60-120 min.
Histology and quantitative cultures of organs.
For histopathologic evaluation of lesions, organs
were fixed in 10070 phosphate-buffered formalin (pH
7.4) immediately after the killing of the animals, em-
bedded in methacrylate, and stained by Giemsa's
method. For quantitative cultures, individual organs
were homogenized with Teflon pestles in 5 ml of
Sabouraud's broth [10] by using a hand drill (CSB
420-E; Scintilla AG, Solothurn, Switzerland) set at
400 rpm. Serial 1:10dilutions of homogenates were
mixed in pour plates with Sabouraud dextrose agar
(Difco) and were read after 48 hr at 37 C.
Evaluation ofthe protective effect ofantimycotic
regimens: statistical analysis. Survival of mice was
recorded daily for at least 40 days after challenge.
The LD values werecomputed by the method of Reed
and Munch [23]. Statistical significance of differ-
ences in survival were assessed by using 2 x k con-
tingency tables with the Bonferroni-j-' statistics ta-
Table 1. The susceptibility of aspergilli to amphotericin B after exposure to various concentrations of ketoconazole
for 8 hr.
MFC after ketoconazole concentration (mg/liter) of*
Fungus 0 0.5 2 4
A. fumigatus 1 0.63 2.5 5.0 5.0 5.0
A. fumigatus 2 0.31 5.0 5.0 5.0
A. fumigatus 3 0.31 1.25 5.0 5.0 5.0
A. fumigatus 4 0.31 1.25 2.5 2.5 5.0
A. fumigatus 5 0.15 1.25 2.5 5.0
A. fumigatus 6 0.63 5.0 5.0 5.0
mean 0.38 3.5 3.75 5.0
A. niger 0.15 2.5 2.5 2.5
A. flavus 0.15 5.0 5.0 -t
* MFC = lowest concentration of amphotericin B (mg/liter) that sterilized microwells. Serial 1:2 dilutions from 10 to 0.07 mg
of amphotericin B/liter were tested in quadruplicate microwells.
t At this concentration ketoconazole was fungicidal.
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Table 2. The influence of the duration and timing of
ketoconazole exposure on the extent of antagonism to
amphotericin B.
Hr of Ketoconazole +
pretreatment amphotericin B MFC (mg/liter)
0 no 0.31
3 no 1.25
6 no 2.5
10 no 5.0
0 yes 0.61
3 yes 2.5
10 yes 10.0
NOTE. One milligram per liter of ketoconazole was added
to microwells with hyphae from A. fumigatus 1, at the indicated
times, before centrifugation of the microplates and replacement
of the culture medium by serial 1:2 dilutions of amphotericin
B (0.15-10 mg/liter). The concentration of ketoconazole added
with amphotericin B was also 1 mg/liter. MFC = lowest con-
centration of amphotericin B that sterilized microwells.
bles for correction of multiple comparisons [24].
Differences between mean values were examined by
Student's t test [24].
Results
Effect ofketoconazole on the fungicidal activity
ofamphotericin B in vitro. Pretreatment of six clin-
ical isolates ofA. fumigatus, or of a strain ofA. fla-
vus and of A. niger, with ketoconazole at concen-
trations corresponding to therapeutic drug levels [21,
22] uniformly suppressed the fungicidal activity of
amphotericin B (table 1).Under the given conditions
this antagonism was dose dependent, with a more
pronounced effect at higher ketoconazole concen-
trations. On the other hand, prolonged incubation
resulted in a more pronounced antagonism at a given
concentration of ketoconazole. When ketoconazole
was only added at the time when amphotericin B was
given to the fungi, antagonism was minimal (table
2) but reproducible (data not shown). When, after
preexposure, ketoconazole was again added with am-
photericin B to the cultures, the minimal fungicidal
concentration of amphotericin B was further in-
creased.
In vivo model ofdisseminated aspergillosis. In-
travenous inoculation of an LD lOo of spores resulted
in a disseminated infection mainly affecting the liver
(1.3 ± 0.8 x 103 cfu/ml of organ homogenate on
day 3 after challenge; mean ± SD from five animals)
and the kidneys (7.3 ± 0.6 x 102 ) with only mini-
mal infection of other organs, such as the brain (two
905
out of five animals with positive culture; 10 cfu/ml
of homogenate). Histopathologically, lesions con-
sisted of anemic infarcts resulting from intravascu-
lar hyphal growth with thrombosis that was accom-
panied by mycelial invasion of the surrounding tissue.
A cellular inflammatory reaction of the fungi was
absent (figure 2). Death occurred within 12days af-
ter challenge, mainly within the first eight days when
neutrophil counts were drastically reduced.
Effects ofketoconazole pretreatment on the pro-
tective activity ofamphotericin B in vivo. To evalu-
ate whether our model of disseminated aspergillo-
sis would be suited to investigating the effects of
ketoconazole on the protective antifungal activity
ofamphotericin B, we challenged mice with 3 x 104
spores from strain no. 1 and then treated the mice
for six days with either 200 mg of ketoconazole/kg
per day or 2 mg of amphotericin B/kg. All (16 of
16)control animals, which received the appropriate
solvents, died within 10days, whereas 15of 16mice
receiving ketoconazole died in the same time period
(ketoconazole vs. control, P = .5). In contrast, none
of the 15mice receiving amphotericin B died within
40 days (P< .(01). Thus ketoconazole, even at high
doses, did not prevent lethal infection, whereas am-
photericin B started 12 hr after infection was com-
pletely protective.
After these preliminary investigations we studied
the effects of pretreating aspergillosis with ketocona-
zole on the subsequent protective activity of am-
photericin B. In a frrst experiment, ketoconazole was
started immediately after challenge and amphoteri-
cin B 24 hr thereafter. As in the previous experiment,
all control animals died, and amphotericin B pro-
tected the majority of mice. Seven of 13mice receiv-
ing first ketoconazole and then amphotericin B plus
ketoconazole, however, died (P < .05). Again,
ketoconazole alone was without effect (figure 3). In
the next experiment, the time of pretreatment of
aspergillosis was prolonged to 48 hr and amphoteri-
cin B was started two days after challenge. While the
delay in therapy reduced the protective effect of am-
photericin B, antagonism of ketoconazole was even
more marked. Furthermore, even when the adminis-
tration of ketoconazole was stopped with the begin-
ning of amphotericin B treatment, antagonism of
the protective effect was still complete (figure 4).
When the same experiment was repeated with an-
other strain ofA. fumigatus, comparable results were
obtained (figure 5). Every experiment had control
groups of at least eight mice receiving either
906 Schaffner and Frick
Figure 2. Hepatic lesion four days
after iv challenge with a lethal dose of
conidia. Top: an hepatic vein filled
with thrombotic material and neigh-
bouring a large necrotic zone (clear
area) with karyorrhexis and karyoly-
sis (x 400). Bottom: at a higher mag-
nification (x 1,000), branching
hyphae are seen in the thrombus with
invasion of the contiguous tissue. Note
the complete absence of a phagocytic
inflammatory response to the hyphae.
ketoconazole or amphotericin B, but no challenge,
in order to monitor deaths unrelated to fungal in-
fection. None of these animals died.
Finally,weinvestigatedwhether antagonism of the
antifungal activity of amphotericin B would also be
reflected by differences in cfu in organ homogenates
obtained from animals of the different therapeutic
groups. Because the liver was the most heavily in-
fected organ, results of quantitative cultures of the
livers are shown (figure 6). Less homogenous, but
still significant, differences reflecting ketoconazole
antagonism of amphotericin B were obtained from
cultures of the kidneys (results not shown).
Discussion
Opportunistic fungal infections have emerged as a
major threat to patients undergoing intensive
chemotherapy for malignancies such as acute my-
elogenous leukemia [1-8]. Thus the question of
prevention of fungal infection in such patients has
become an important concern. Removal of fungal
spores from the patients' environment by filtration
of the air is probably successful in reducing the in-
cidence of infections with molds [25] but requires
expensive equipment and cannot be expected to re-
duce the incidence of "endogenous" infections with
Ketoconazole and Amphotericin B 907
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Figure 4. Abolishment of the protective activity of am-
photericin B by ketoconazole. The figure shows the sur-
vival of mice (n = 12-14 in each group) challenged with
2.4 x 104 cfu of A. fumigatus 1. Ketoconazole (100
mg/kg per day) was again started immediately after
challenge and either stopped after 48 hr, when therapy
with amphotericin B for six days was begun, or continued
throughout therapy with amphotericin B. • = control;
• = amphotericin B plus ketoconazole; * = amphoteri-
cin B after ketoconazole; A = amphotericin B only. Am-
photericin B vs. both groups receiving ketoconazole
combined, P = .0019 (Fischer's exact test); amphoteri-
cin B alone vs. each other group, P < .025 (Bonferroni-
X2 test corrected for multiple comparisons).
[15]. The in vitro interaction between imidazoles and
amphotericin B appears, however, to depend on the
experimental design. The sequence of exposure to
the two drugs appears to be of particular importance.
It has been shown with Candida albicans and
miconazole that antagonism is more marked when
the fungal cells are first exposed to the imidazole
and then exposed to amphotericin B, as compared
with the reversed sequence [14]. This observation is
supported by our finding that pretreatment with
ketoconazole increased the minimal fungicidal ac-
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Figure 3. Antagonism of the protective activity of am-
photericin B by ketoconazole. The figure shows the sur-
vival of mice (n = 13 in each group) that were challenged
with 4.2 x 10"cfu of A. fumigatus 1. Ketoconazole (100
mg/kg per day) was given for eight days (starting immedi-
ately after challenge) and amphotericin B (2 mg/kg per
day) was given for six days (starting 24 hr after challenge).
Amphotericin B vs. control, P < .01; vs. ketoconazole,
P < .01; vs. ketoconazole plus amphotericin B, P < .05
(Bonferroni-j' test corrected for multiple comparisons).
yeasts. Thus two different approaches have been pro-
posed to study the problem of opportunistic fungal
infections in cancer patients; on one hand, chemo-
prophylaxis with ketoconazole [12, 18, 19]- an oral
systemic antifungal agent with few side effects-
and on the other hand, in bacterial infections, early
empirical therapy with amphotericin B in neutro-
penic patients with febrile episodes not responding
to antibacterial agents [1, 26].
Ketoconazole, like other imidazoles, has the poten-
tial to antagonize the antifungal activity of am-
photericin B in vitro [13-15], possibly by inhibiting
ergosterol synthesis and thus depriving amphoteri-
cin B of its binding site on the fungal cell membrane
908 Schaffner and Frick
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interaction: amphotericin B being more active at
first, when the ergosterol composition of the cell
membrane is still unaffected, and the imidazole be-
ing still active severaldays after amphotericin B has
been inactivated by oxidation. In any event, these
discrepancies show that the clinical relevance of .the
in vitro interaction of imidazoles with amphoteri-
cin B can only be appreciated by in vivo experiments
corresponding to clinical therapy.
Our studies of the effects of ketoconazole on the
efficacy of subsequent therapy with amphotericin
B in a model of disseminated aspergillosis clearly
document that the antagonism of the fungicidal ac-
tivity of amphotericin B by prior exposure to
ketoconazole is operative in vivo. In accordance with
the in vitro studies, pretreatment with ketoconazole
Figure 6. Comparison of cfu in liver homogenates of
mice treated with different antimycotic regimens. In ex-
periment 1 mice were challenged with an LD lO O of
A. fumigatus 1 and killed 8 hr after the first dose of am-
photericin B. In experiment 2 mice were challenged with
an LD IO O of A. fumigatus 4 and killed 8 hr after the se-
cond dose of amphotericin B. C = cfu from control mice
that did not receive antifungal drugs; K = cfu from mice
that received three daily doses of ketoconazole (loo mg/
kg); KA = cfu from mice that received ketoconazole (100
mg/kg per day) plus amphotericin B (2 mg/kg per day)
for two days; KAK = cfu from mice that received first
ketoconazole and then ketoconazole plus amphotericin
B (same doses as above). A vs. KA in each experiment,
P < .01; A vs. C, P < .01; A vs. KAK, P < .01; KA vs.
KAK, not significant; K vs. C, not significant two-tailed
Student's t test).
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Figure 5. Abolishment of the protective activity of am-
photericin B by ketoconazole. The figure shows the sur-
vival of mice (n = 12 in each group) challenged with
3.5 x 104 cfu of A. fumigatus 4. This experiment is iden-
tical to the experiment in figure 4 except that the
ketoconazole dose was 150 mg/kg per day. Amphoteri-
cin B vs. both groups receiving ketoconazole, P = .0006
(Fischer's exact test); amphotericin B alone vs. amphoteri-
cin B after ketoconazole, P < .05; vs. the two other
groups, P < .01 (Bonferroni-v' test corrected for multi-
ple comparisons).
tivity of amphotericin B much more than did simul-
taneous exposure (table 2). This observation appears
logical if inhibition of ergosterol synthesis by the im-
idazole is assumed to be responsible for the interac-
tion; antagonism would only be expected to be ef-
fectiveafter the sterol composition of the fungal cell
membrane had been altered. In contrast to an-
tagonism, synergism was found in experiments in
which fungi wereexposed over severaldays to a com-
bination of amphotericin B with an imidazole [14,
27]. Interpretation of these studies is difficult, how-
ever, because amphotericin B is not stable in vitro
[28], and no attempts were made to replace the ac-
tivity lost due to prolonged incubation. Thus it ap-
pears that these experiments might reflect the se-
quential activity of the two drugs rather than an
Ketoconazole and Amphotericin B
prevented the fungicidal activity of amphotericin B
in vivo, as shown by quantitative cultures of liver
homogenates (figure 6) and completely abolished the
protective effect of amphotericin B (figures 4 and
5). The extent of the antagonism in the animal model
suggests that the interaction might also be clinically
relevant.
Antagonism of amphotericin B by ketoconazole
has been shown previously in murine aspergillosis,
but the effect was not dramatic. The results of these
investigations are, however, difficult to compare with
our study because the mice were not immunosup-
pressed, the drugs were given simultaneously, and
only a fraction of our amphotericin B dose was given
to the animals [29]. Starting from the question of
whether ketoconazole prophylaxis would interfere
with subsequent therapy of a fungal breakthrough
infection, we selected experimental conditions that
would permit extrapolation to the clinical problem.
We chose, therefore, a model of aspergillosis in which
elimination of phagocytic defense resulted in histo-
pathologic lesions comparable to clinical disease [12]
and selected doses of antimycotic drugs corre-
sponded to clinical therapy.
The efficacy of ketoconazole prophylaxis for
prevention of invasive opportunistic mycosis in pa-
tients at high risk is not established. In a small but
careful study, Brincker [19] found that 400 mg of
ketoconazole significantly reduced the incidence of
oral thrush in cancer patients but that two of 19 pa-
tients treated with ketoconazole (a fraction identi-
cal to that of the placebo group) developed systemic
candidiasis. Both patients in the ketoconazole group
succumed to the infection in spite of therapy with
amphotericin Band 5-flucytosine, whereas the two
patients in the placebo group were cured. This ob-
servation might not be fortuitous because an-
tagonism of amphotericin B by ketoconazole is as
marked for C. albicans as it is for Aspergilli (A. S.,
unpublished observations) [15].A recent study from
England [18] compared the efficacy of ketoconazole
with oral amphotericin B and nystatin and suggested
there was a reduction in the incidence of fungal in-
fection in high-risk patients receiving ketoconazole.
This study fails, however, to provide data that per-
mit discrimination between superficial fungal infec-
tions, such as thrush, and disseminated opportunis-
tic mycoses. Other studies show a high rate of
breakthrough infection under ketoconazole prophy-
laxis [12, 30] in addition to a high-failure rate of am-
photericin B in such patients [12].
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In consideration of the available clinical ex-
perience with ketoconazole prophylaxis, our data (1)
show that ketoconazole might significantly interfere
with subsequent therapy of aspergillosis with am-
photericin B, making this form of prophylaxis un-
suitable for centers in which aspergilli are important
pathogens; (2) indicate that ketoconazole prophy-
laxis, which has few side effects on the patient, might
have an important, undesired effect of reducing the
susceptibility of fungi to the only antimycotic agent
shown to be effective in most invasive opportunistic
mycoses; and (3) point out that future clinical evalu-
ation of imidazoles for fungal prophylaxis should
include analysis of the efficacy of amphotericin B
therapy in patients with breakthrough mycosis.
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